-
Je něco špatně v tomto záznamu ?
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
A. Xochelli, P. Baliakas, I. Kavakiotis, A. Agathangelidis, LA. Sutton, E. Minga, S. Ntoufa, E. Tausch, XJ. Yan, T. Shanafelt, K. Plevova, M. Boudjogra, D. Rossi, Z. Davis, A. Navarro, Y. Sandberg, FJ. Vojdeman, L. Scarfo, N. Stavroyianni, A....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 1995 do Před 1 rokem
Freely Accessible Science Journals
od 1995
Open Access Digital Library
od 1995-01-01
Open Access Digital Library
od 1995-01-01
- MeSH
- antigeny CD38 genetika imunologie MeSH
- chronická lymfatická leukemie genetika imunologie patologie MeSH
- imunogenetika MeSH
- lidé MeSH
- regulace genové exprese u nádorů imunologie MeSH
- sekvence aminokyselin genetika MeSH
- somatická hypermutace imunoglobulinových genů genetika MeSH
- těžké řetězce imunoglobulinů genetika imunologie MeSH
- variabilní oblast imunoglobulinu genetika imunologie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Purpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication.Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34-expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes.Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P < 0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively).Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management. Clin Cancer Res; 23(17); 5292-301. ©2017 AACR.
1st Department of Propaedeutic Medicine University of Athens Athens Greece
2nd Medical Department University Hospital Schleswig Holstein Campus Kiel Kiel Germany
Central European Institute of Technology Masaryk University Brno Czech Republic
Department of Haemato Oncology Belfast City Hospital Belfast United Kingdom
Department of Haematology Royal Bournemouth Hospital Bournemouth United Kingdom
Department of Hematology Department of Medicine Mayo Clinic Rochester Minnesota
Department of Hematology Hopital Pitie Salpetriere and University Pierre et Marie Curie Paris France
Department of Hematology Rigshospitalet Copenhagen Denmark
Department of Immunology Erasmus MC University Medical Center Rotterdam Rotterdam the Netherlands
Department of Immunology Mayo Clinic Rochester Minnesota United States
Department of informatics Aristotle University of Thessaloniki Thessaloniki Greece
Department of Internal Medicine 3 Ulm University Ulm Germany
Department of Medicine Solna Clinical Epidemiology Unit Karolinska Institutet Stockholm Sweden
Feinstein Institute for Medical Research Northwell Health Manhasset New York
Hematology Department and HCT Unit G Papanicolaou Hospital Thessaloniki Greece
Hematology Department Nikea General Hospital Piraeus Greece
Institute of Applied Biosciences CERTH Thessaloniki Greece
Institute of Molecular Genetics and Genetic Engineering University of Belgrade Belgrade Serbia
Laboratory of Medical Informatics Aristotle University of Thessaloniki Thessaloniki Greece
Lund University and Hospital Department of Hematology Lund Stem Cell Center Lund Sweden
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18024995
- 003
- CZ-PrNML
- 005
- 20180712100303.0
- 007
- ta
- 008
- 180709s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1158/1078-0432.CCR-16-3100 $2 doi
- 035 __
- $a (PubMed)28536306
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Xochelli, Aliki $u Institute of Applied Biosciences, CERTH, Thessaloniki, Greece. Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
- 245 10
- $a Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes / $c A. Xochelli, P. Baliakas, I. Kavakiotis, A. Agathangelidis, LA. Sutton, E. Minga, S. Ntoufa, E. Tausch, XJ. Yan, T. Shanafelt, K. Plevova, M. Boudjogra, D. Rossi, Z. Davis, A. Navarro, Y. Sandberg, FJ. Vojdeman, L. Scarfo, N. Stavroyianni, A. Sudarikov, S. Veronese, T. Tzenou, T. Karan-Djurasevic, M. Catherwood, D. Kienle, M. Chatzouli, M. Facco, J. Bahlo, C. Pott, LB. Pedersen, L. Mansouri, KE. Smedby, CC. Chu, V. Giudicelli, MP. Lefranc, P. Panagiotidis, G. Juliusson, A. Anagnostopoulos, I. Vlahavas, D. Antic, L. Trentin, M. Montillo, C. Niemann, H. Döhner, AW. Langerak, S. Pospisilova, M. Hallek, E. Campo, N. Chiorazzi, N. Maglaveras, D. Oscier, G. Gaidano, DF. Jelinek, S. Stilgenbauer, I. Chouvarda, N. Darzentas, C. Belessi, F. Davi, A. Hadzidimitriou, R. Rosenquist, P. Ghia, K. Stamatopoulos,
- 520 9_
- $a Purpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication.Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34-expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes.Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P < 0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively).Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management. Clin Cancer Res; 23(17); 5292-301. ©2017 AACR.
- 650 _2
- $a antigeny CD38 $x genetika $x imunologie $7 D051997
- 650 _2
- $a sekvence aminokyselin $x genetika $7 D000595
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese u nádorů $x imunologie $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunogenetika $7 D007125
- 650 _2
- $a těžké řetězce imunoglobulinů $x genetika $x imunologie $7 D007143
- 650 _2
- $a variabilní oblast imunoglobulinu $x genetika $x imunologie $7 D007135
- 650 _2
- $a chronická lymfatická leukemie $x genetika $x imunologie $x patologie $7 D015451
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a somatická hypermutace imunoglobulinových genů $x genetika $7 D027041
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Baliakas, Panagiotis $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
- 700 1_
- $a Kavakiotis, Ioannis $u Department of informatics, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- 700 1_
- $a Agathangelidis, Andreas $u Institute of Applied Biosciences, CERTH, Thessaloniki, Greece. Division of Experimental Oncology and Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- 700 1_
- $a Sutton, Lesley-Ann $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Minga, Eva $u Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.
- 700 1_
- $a Ntoufa, Stavroula $u Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.
- 700 1_
- $a Tausch, Eugen $u Department of Internal Medicine III, Ulm University, Ulm, Germany.
- 700 1_
- $a Yan, Xiao-Jie $u Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York.
- 700 1_
- $a Shanafelt, Tait $u Department of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
- 700 1_
- $a Plevova, Karla $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Boudjogra, Myriam $u Department of Hematology, Hopital Pitie-Salpetriere and University Pierre et Marie Curie, Paris, France.
- 700 1_
- $a Rossi, Davide $u Division of Haematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
- 700 1_
- $a Davis, Zadie $u Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom.
- 700 1_
- $a Navarro, Alba $u Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain.
- 700 1_
- $a Sandberg, Yorick $u Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
- 700 1_
- $a Vojdeman, Fie Juhl $u Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
- 700 1_
- $a Scarfo, Lydia $u Division of Experimental Oncology and Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- 700 1_
- $a Stavroyianni, Niki $u Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
- 700 1_
- $a Sudarikov, Andrey $u National Research Center for Hematology, Moscow, Russia.
- 700 1_
- $a Veronese, Silvio $u Molecular Pathology Unit and Haematology Department, Niguarda Cancer Center, Niguarda Ca' Granda Hospital, Milan, Italy.
- 700 1_
- $a Tzenou, Tatiana $u First Department of Propaedeutic Medicine, University of Athens, Athens, Greece.
- 700 1_
- $a Karan-Djurasevic, Teodora $u Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
- 700 1_
- $a Catherwood, Mark $u Department of Haemato-Oncology, Belfast City Hospital, Belfast, United Kingdom.
- 700 1_
- $a Kienle, Dirk $u Department of Internal Medicine III, Ulm University, Ulm, Germany.
- 700 1_
- $a Chatzouli, Maria $u Hematology Department, Nikea General Hospital, Piraeus, Greece.
- 700 1_
- $a Facco, Monica $u Department of Medicine, Hematology and Clinical Immunology Branch, Padua University School of Medicine, Padova, Italy.
- 700 1_
- $a Bahlo, Jasmin $u Department I of Internal Medicine and Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany.
- 700 1_
- $a Pott, Christiane $u Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
- 700 1_
- $a Pedersen, Lone Bredo $u Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
- 700 1_
- $a Mansouri, Larry $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Smedby, Karin E $u Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Chu, Charles C $u Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York.
- 700 1_
- $a Giudicelli, Véronique $u IMGT®, the international ImMunoGeneTics information system®, Université de Montpellier, LIGM, Institut de Génétique Humaine IGH, UPR CNRS 1142, Montpellier, France.
- 700 1_
- $a Lefranc, Marie-Paule $u IMGT®, the international ImMunoGeneTics information system®, Université de Montpellier, LIGM, Institut de Génétique Humaine IGH, UPR CNRS 1142, Montpellier, France.
- 700 1_
- $a Panagiotidis, Panagiotis $u First Department of Propaedeutic Medicine, University of Athens, Athens, Greece.
- 700 1_
- $a Juliusson, Gunnar $u Lund University and Hospital Department of Hematology, Lund Stem Cell Center, Lund, Sweden.
- 700 1_
- $a Anagnostopoulos, Achilles $u Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
- 700 1_
- $a Vlahavas, Ioannis $u Department of informatics, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- 700 1_
- $a Antic, Darko $u Clinic for Hematology, Clinical Center, Belgrade, Serbia. Medical faculty, University of Belgrade, Belgrade, Serbia.
- 700 1_
- $a Trentin, Livio $u Department of Medicine, Hematology and Clinical Immunology Branch, Padua University School of Medicine, Padova, Italy.
- 700 1_
- $a Montillo, Marco $u Molecular Pathology Unit and Haematology Department, Niguarda Cancer Center, Niguarda Ca' Granda Hospital, Milan, Italy.
- 700 1_
- $a Niemann, Carsten $u Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
- 700 1_
- $a Döhner, Hartmut $u Department of Internal Medicine III, Ulm University, Ulm, Germany.
- 700 1_
- $a Langerak, Anton W $u Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
- 700 1_
- $a Pospisilova, Sarka $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Hallek, Michael $u Department I of Internal Medicine and Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany.
- 700 1_
- $a Campo, Elias $u Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain.
- 700 1_
- $a Chiorazzi, Nicholas $u Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York.
- 700 1_
- $a Maglaveras, Nikos $u Laboratory of Medical Informatics, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- 700 1_
- $a Oscier, David $u Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom.
- 700 1_
- $a Gaidano, Gianluca $u Division of Haematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
- 700 1_
- $a Jelinek, Diane F $u Department of Immunology, Mayo Clinic, Rochester, Minnesota, United States.
- 700 1_
- $a Stilgenbauer, Stephan $u Department of Internal Medicine III, Ulm University, Ulm, Germany.
- 700 1_
- $a Chouvarda, Ioanna $u Laboratory of Medical Informatics, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- 700 1_
- $a Darzentas, Nikos $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Belessi, Chrysoula $u Hematology Department, Nikea General Hospital, Piraeus, Greece.
- 700 1_
- $a Davi, Frederic $u Department of Hematology, Hopital Pitie-Salpetriere and University Pierre et Marie Curie, Paris, France.
- 700 1_
- $a Hadzidimitriou, Anastasia $u Institute of Applied Biosciences, CERTH, Thessaloniki, Greece. anastasiaxtz@gmail.com. Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
- 700 1_
- $a Rosenquist, Richard $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Ghia, Paolo $u Division of Experimental Oncology and Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy. Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milan, Italy.
- 700 1_
- $a Stamatopoulos, Kostas $u Institute of Applied Biosciences, CERTH, Thessaloniki, Greece. Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
- 773 0_
- $w MED00001121 $t Clinical cancer research an official journal of the American Association for Cancer Research $x 1078-0432 $g Roč. 23, č. 17 (2017), s. 5292-5301
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28536306 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180712100556 $b ABA008
- 999 __
- $a ok $b bmc $g 1317126 $s 1021916
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 23 $c 17 $d 5292-5301 $e 20170523 $i 1078-0432 $m Clinical cancer research $n Clin Cancer Res $x MED00001121
- LZP __
- $a Pubmed-20180709
